Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer
US10500290B2 · kind B2 · utility
0Cited by
9References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 21, 2015 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | Aug 21, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to EGFR-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents. In one aspect, the disclosure provides reagents consisting essentially of a peptide QRHKPRE (SEQ ID NO: 1), HAHRSWS (SEQ ID NO: 2), YLTMPTP (SEQ ID NO: 3), TYPISFM (SEQ ID NO: 4), KLPGWSG (SEQ ID NO: 5), IQSPHFF (SEQ ID NO: 6), YSIPKSS (SEQ ID NO: 7), SHRNRPRNTQPS (SEQ ID NO: 8), NRHKPREKTFTD (SEQ ID NO: 9).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.